NCT04670471View on ClinicalTrials.gov

Assessment of the Pharmacodynamic and Pharmacokinetic Interaction of Remimazolam and Remifentanil

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 13, 2021

Primary Completion Date

January 28, 2022

Study Completion Date

January 28, 2022

Conditions
Anesthesia
Interventions
DRUG

Remimazolam

Remimazolam is an intravenous anaesthetic and sedative drug. Remimazolam exhibits its anaesthetic effects via the benzodiazepine binding site at the GABAA receptor.

DRUG

Remifentanil

Remifentanil is a commonly used opioid in anaesthetic practice. It is a potent and fast-acting analgesic.

Trial Locations (1)

9700

University Medical Center Groningen, Groningen

All Listed Sponsors
collaborator

University Medical Center Groningen

OTHER

collaborator

QPS Holdings LLC

INDUSTRY

lead

Paion UK Ltd.

INDUSTRY